Abstract
Sporadic colorectal cancer (CRC) is a fatal disease, mostly known as the silent killer, due to the fact that this disease is asymptomatic before diagnosis in advanced stage. Screening and the early detection of CRC and colorectal adenoma (CRA) by non-aggressive molecular biomarkers’ signature is useful for improvement of survival rate in CRC patients. To achieve such a goal, a better understanding of distinct molecular abnormalities as candidate biomarkers in CRC development is crucial. In this study, seventy-five archived FFPE CRC samples, including colorectal adenocarcinoma, adenomatous polyps (adenoma), and adjacent non-neoplastic mucosa were collected for the investigation by Sanger sequencing at the DNA level and by real-time PCR at the RNA level. The results of the KRAS mutational analysis have shown that the majority of somatic mutations in the KRAS affect only one codon, mainly codon 12(p.G12D) with low frequency in adenomas (13.3%) versus CRCs (36%). The results of dysregulated epigenetic changes of miR-21 clearly showed upregulation of expression in colorectal adenocarcinoma, compared to non-neoplastic mucosa, in colorectal adenoma vs non-neoplastic mucosa: (p < 0.001) and in CRC versus adenoma (p < 0.001); while miR-148a expression were significantly downregulated in CRC, compared to non-neoplastic mucosa, in colorectal adenoma vs non-neoplastic mucosa, and in adenoma vs CRC (p < 0.001). Our findings support the important role of miR-21 in stages I–II of CRC, and the KRAS G12D mutant, and differential miR-148a expression, in advanced stages of CRC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armaghany T, Wilson JD, Chu Q, Mills G (2012) Genetic alterations in colorectal cancer. GCR 5(1):19
Baltruskeviciene ED et al (2017) Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. BMC Cancer 17(1):607. https://doi.org/10.1186/s12885-017-3575-z
Boutin AT et al (2017) Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. https://doi.org/10.1101/gad.293449.116
Bullock M et al (2013) Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 4(6):e684. https://doi.org/10.1038/cddis.2013.213
Chuang T P et al. (2016). Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression. Oncotarget 7(29): 45803. https://doi.org/10.18632/oncotarget. 9960
Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14(8):16365–16385. https://doi.org/10.3390/ijms140816365
Enquist IB et al (2014) Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nat Commun 5:3530. https://doi.org/10.1038/ncomms4530
Eslamizadeh S et al (2018) The Role of MicroRNA Signature as Diagnostic Biomarkers in Different Clinical Stages of Colorectal Cancer. Cell J (Yakhteh) 20:220–230. https://doi.org/10.22074/cellj.2018.5366
Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4):1079–1099. https://doi.org/10.1053/j.gastro.2008.07.076
Han D et al (2017) Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 66(4):1151–1164. https://doi.org/10.1002/hep.29270
Hibino Y et al (2015) Significance of miR-148a in colorectal neoplasia: downregulation of miR-148a contributes to the carcinogenesis and cell invasion of colorectal cancer. Pathobiology 82(5):233–241. https://doi.org/10.1159/000438826
Knickelbein K, Zhang L (2015) Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2(1):4–12. https://doi.org/10.1016/j.gendis.2014.10.002
Konda K et al (2014) Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PLoS ONE 9(8):e103822. https://doi.org/10.1371/journal.pone.0103822
Lee KS et al (2016) Stromal expression of microRNA-21 in advanced colorectal cancer patients with distant metastases. J Pathol Transl Med 50(4):270. https://doi.org/10.4132/jptm.2016.03.19
Li W et al (2015) Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 15(1):340. https://doi.org/10.1186/s12885-015-1345-3
Lionis C, Petelos E (2011) Early detection of colorectal cancer: barriers to screening in the primary care setting, Oxford University Press. Family Pract 28:589–591. https://doi.org/10.1093/fampra/cmr110
Liu X, Jakubowski M, Hunt JL (2011) KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 135(2):245–252. https://doi.org/10.1309/AJCP7FO2VAXIVSTP
Liu X et al (2018) Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation. Mol Ther Nucleic Acids 13:312–321. https://doi.org/10.1016/j.omtn.2018.09.010
Lorentzen JA et al (2016) Oncogene mutations in colorectal polyps identified in the Norwegian colorectal cancer prevention (NORCCAP) screening study. Clin Med Insights 9:S40143. https://doi.org/10.4137/CPath.s40143
Margetis N, Kouloukoussa M, Pavlou K, Vrakas S, Mariolis-Sapsakos T (2017) K-ras mutations as the earliest driving force in a subset of colorectal carcinomas. Vivo 31(4):527–542. https://doi.org/10.21873/invivo.11091
Nielsen BS et al (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metast 28(1):27–38. https://doi.org/10.1007/s10585-010-9355-7
Palmirotta R et al (2011) Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer. Folia Histochem Cytobiol 49(4):729–733. https://doi.org/10.5603/FHC.2011.0097
Palomba G et al (2016) Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncol Lett 12(2):1415–1421. https://doi.org/10.3892/ol.2016.4798
Payandeh M et al (2017) The prevalence of KRAS mutation in colorectal cancer patients in Iranian population: a systematic review and meta-analysis study. Biomed Res Therapy 4(10):1693–1704. https://doi.org/10.15419/bmrat.v4i10.374
Peng Q et al (2017) The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 8(27):44893. https://doi.org/10.18632/oncotarget.16488
Price C, Chen J (2014) MicroRNAs in cancer biology and therapy: current status and perspectives. Genes Dis 1(1):53–63. https://doi.org/10.1016/j.gendis.2014.06.004
Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-1, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12(1):505. https://doi.org/10.1186/1471-2407-12-505
Soto Y et al (2016) Molecular evidence of high-risk human papillomavirus infection in colorectal tumours from Cuban patients. Memórias do Instituto Oswaldo Cruz 111(12):731–736. https://doi.org/10.1590/0074-02760160217
Sun G et al (2016) Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol. Oncotarget 7(4):3857. https://doi.org/10.18632/oncotarget.6460
Takahashi M et al (2012) The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PloS ONE 7(10):e46684. https://doi.org/10.1371/journal.pone.0046684
Tan C, Du X (2012) KRAS mutation testing in metastatic colorectal cancer. WJG 18(37):5171. https://doi.org/10.3748/wjg.v18.i37.5171
Ulintz PJ, Greenson JK, Wu R, Fearon ER, Hardiman KM (2018) Lymph node metastases in colon cancer are polyclonal. Clin Cancer Res 24(9):2214–2224. https://doi.org/10.1158/1078-0432.CCR-17-1425
Uratani R et al (2016) Diagnostic potential of cell-free and exosomal microRNAs in the identification of patients with high-risk colorectal adenomas. PloS ONE 11(10):e0160722. https://doi.org/10.1371/journal.pone.0160722
Wu Y et al (2017) MicroRNA-21 (Mir-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem 43(3):945–958. https://doi.org/10.1159/000481648
Yamagishi H, Kuroda H, Imai Y, Hiraishi H (2016) Molecular pathogenesis of sporadic colorectal cancers. Chin J Cancer 35(1):4. https://doi.org/10.1186/s40880-015-0066-y
Ye JX et al (2015) KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. WJG 21:1595. https://doi.org/10.3748/wjg.v21.i5.1595
Yuan H et al (2017) Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. Oncotarget 8(28):46565. https://doi.org/10.18632/oncotarget.15425
Zauber P, Marotta S, Sabbath-Solitare M (2013) KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. Int J Mol Epidemiol Genetics 4(1):1
Acknowledgements
We thank our colleagues at the Department of Gastrointestinal Surgery and Institute of Digestive Surgery for providing tissue samples and pathological records. We would like to thank all colleagues who performed research in the field of microRNA and colorectal cancer. This study was financially supported by the Shiraz University of Medical Sciences [with Grant Number 94-01-01-10626]
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Igder, S., Mohammadiasl, J. & Mokarram, P. Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions. Biochem Genet 57, 767–780 (2019). https://doi.org/10.1007/s10528-019-09918-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-019-09918-0